Voriconazole pharmacokinetics and pharmacodynamics in children

Clinical Infectious Diseases

Volumn 50, Issue 1, 2010, Pages 27-36

  Neely, Michael ^a,b   Rushing, Teresa ^b   Kovacs, Andrea ^a   Jelliffe, Roger ^a   Hoffman, Jill ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; VORICONAZOLE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; LIVER TOXICITY; MALE; MICHAELIS MENTEN KINETICS; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SIMULATION; SURVIVAL;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; HUMANS; INFANT; LINEAR MODELS; MALE; MODELS, BIOLOGICAL; MYCOSES; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TRIAZOLES; YOUNG ADULT;

EID: 72049130592     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648679     Document Type: Article

References (18)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415 (Pubitemid 34851833)
2. Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008; 27:1083-1088
3. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166-2172 (Pubitemid 38691615)
4. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53:935-944
5. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-571 (Pubitemid 34165316)
6. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211 (Pubitemid 351269158)
7. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-1572
8. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243 (Pubitemid 43146453)
9. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30:167-172
10. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61:17-25.
11. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 49:196-204.
12. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821
13. EPARs for authorised medicinal products for human use-Vfend. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/ vfend/vfend.htm. Accessed 13 January 2009.
14. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169
15. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44:819-826
16. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21:735-750
17. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56(Suppl 1):17-23. (Pubitemid 37491729)
18. Destino L, Sutton DA, Helon AL, et al. Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury. Ann Clin Microbiol Antimicrob 2006; 5:21.